Editas Medicine
NASDAQ: EDITCambridge, US · Founded 2013 · 2 known investors
Editas Medicine develops gene-editing medicines using CRISPR technology to treat serious genetic diseases. The company discovers, develops, and manufactures genomic medicines for patients worldwide.
Founders & leadership
KB
Katrine BosleyinExecutive
VM
Vic MyerNamed on SEC filing
AG
Alexandra GlucksmannNamed on SEC filing
DC
Douglas ColeNamed on SEC filing
KB
Kevin BittermanNamed on SEC filing
AH
Andrew HackNamed on SEC filing
AB
Alexis BorisyNamed on SEC filing
Board
BN
Boris NikolicBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$120M disclosed across 1 round · 2015
▶$120MraisedAug 2015 · 43 investors · BiotechnologyRule 506(b)
▶$120MraisedAug 2015 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Katrine BosleyExecutive Officer, Director
- Vic MyerExecutive Officer
- Alexandra GlucksmannExecutive Officer
- Douglas ColeDirector
- Kevin BittermanDirector
- Andrew HackExecutive Officer
- Boris NikolicDirector
- Alexis BorisyDirector
- Offering amount
- $120M
- Amount sold
- $120M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
CRISPR54 shared keywordsCRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology. It is led by a management team, board of directors, and scientific founders from the biotech and pharmaceutical industries.
Synthego49 shared keywordsSynthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.
Companies competing with Editas Medicine for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Editas Medicine do?
- Editas Medicine develops gene-editing medicines using CRISPR technology to treat serious genetic diseases. The company discovers, develops, and manufactures genomic medicines for patients worldwide.
- Who are Editas Medicine's investors?
- Editas Medicine's investors include EcoR1 Capital, Sofinnova Ventures.
- How much funding has Editas Medicine raised?
- Editas Medicine has disclosed $120M raised across 1 round.
- Where is Editas Medicine headquartered?
- Editas Medicine is headquartered in Cambridge, US.